- Home
- NYC vs BEAT Comparison
NYC vs BEAT Comparison
Compare NYC & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NYC | BEAT |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5M | 27.7M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NYC | BEAT |
|---|---|---|
| Price | $7.21 | $0.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.63 |
| AVG Volume (30 Days) | 31.7K | ★ 432.0K |
| Earning Date | 04-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.28 | 15.07 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $56.73 | N/A |
| Revenue Next Year | N/A | $315.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.63 | $0.48 |
| 52 Week High | $13.97 | $4.00 |
Technical Indicators
Market Signals| Indicator | NYC | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 34.61 | 37.99 |
| Support Level | N/A | N/A |
| Resistance Level | $8.69 | $0.63 |
| Average True Range (ATR) | 0.63 | 0.04 |
| MACD | -0.21 | 0.00 |
| Stochastic Oscillator | 14.20 | 3.81 |
Price Performance
Historical ComparisonAbout NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.